AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9814730
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 800 microg once daily
Trial: 9814730
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 400 microg twice daily
Trial: 27637737
Drug: Overdentures supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overdentures supported and retained by cantilevered bars on two canine implants (Group I)
Trial: 27637737
Drug: Overdentures retained
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Overdentures retained by straight bars on two canine implants and supported by two-first molar implants (Group II)
Trial: 24284154
Drug: Preoperative Radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative Radiation Therapy (RT)
Trial: 24284154
Drug: Postoperative Radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative Radiation Therapy (RT)
Trial: 24284154
Drug: No Radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Radiation Therapy (RT)
Trial: 11358648
Drug: Estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol valerate (2 mg/day)
Trial: 11358648
Drug: Estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol valerate (2 mg/day) + Dienogest (2 mg/day)
Trial: 9000164
Drug: 0.45% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45% saline oral ingestion (ORAL)
Trial: 9000164
Drug: 0.45% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45% saline infusion (i.v.)
Trial: 31343548
Drug: Beetroot Juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot Juice (BEET) 400-mg nitrate
Trial: 31343548
Drug: Citrulline Malate
RxNorm normalized name: CITRULLINE MALATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrulline Malate (CitMal) 8 g
Trial: 27853809
Drug: Ciraparantag (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciraparantag (100 to 300 mg IV)
Trial: 23553596
Drug: deferasirox 5
RxNorm normalized name: deferasirox 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: deferasirox 5 mg/kg/day
Trial: 23553596
Drug: deferasirox 10
RxNorm normalized name: Deferasirox 100 mg dispersible oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: deferasirox 10 mg/kg/day
Trial: 23553596
Drug: deferasirox 20
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: deferasirox 20 mg/kg/day (dose-escalated from 10 mg/kg/day at Week 24)
Trial: 23553596
Drug: deferasirox >12.5-≤17.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: deferasirox >12.5-≤17.5 mg/kg/day
Trial: 23553596
Drug: deferasirox dosing
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: deferasirox dosing strategies
Trial: 21464362
Drug: CALM (cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CALM (cognitive behavior therapy and pharmacotherapy recommendations)
Trial: 16688562
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose Memory Training Control group (n=16)
Trial: 11769634
Drug: Sibutramine 10
RxNorm normalized name: sibutramine 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 10 mg once a day
Trial: 9263380
Drug: Sirolimus 3
RxNorm normalized name: temsirolimus 30 mg/3 mL (10 mg/mL) (first dilution) INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus 3 mg/m2
Trial: 9263380
Drug: Sirolimus 5
RxNorm normalized name: SIROLIMUS 5 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION [FYARRO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus 5 mg/m2
Trial: 9263380
Drug: Sirolimus 10
RxNorm normalized name: sirolimus 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus 10 mg/m2
Trial: 9263380
Drug: Sirolimus 15
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus 15 mg/m2
Trial: 8513962
Drug: Low-dose cyclic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclic oral contraceptive (n = 28)
Trial: 3799579
Drug: Prednisone alone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone alone (Treatment A)
Trial: 3799579
Drug: Prednisone with
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone with sucralfate (Treatment B)
Trial: 3799579
Drug: Prednisone with
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone with sucralfate administered 2 h after (Treatment C)
Trial: 24163147
Drug: Decision Aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision Aid (DA) for dabigatran vs warfarin
Trial: 20883736
Drug: PCV7+MnCC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV7+MnCC vaccine
Trial: 17690599
Drug: Paliperidone extended-release
RxNorm normalized name: Paliperidone Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone extended-release 9 mg/day
Trial: 11851743
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTX‐A) injections
Trial: 11851734
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no BTX‐A injections)
Trial: 9745864
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) 30 U/m2 per week
Trial: 7803226
Drug: Hypnotic suggestions
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic suggestions to increase cutaneous blood flow
Trial: 7803226
Drug: Hypnotic suggestions
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic suggestions to decrease cutaneous blood flow
Trial: 30200394
Drug: ORS⁺Lr&amp;Z (Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS⁺Lr&amp;Z (Oral Rehydration Solution enriched with Lactobacillus reuteri DSM 17938 and zinc)
Trial: 27232649
Drug: Oral betrixaban
RxNorm normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral betrixaban (80 mg once daily for 35 to 42 days)
Trial: 27232649
Drug: Subcutaneous enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous enoxaparin (40 mg once daily for 10±4 days)
Trial: 25306266
Drug: Conventional yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional yogurt (300 g/d)
Trial: 22574586
Drug: Mesalazine enteric
RxNorm normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine enteric coated tablet (MSRT, 1.0 g, 4 times daily) in the active stage, MSRT (0.5 g, three times daily) in the remission stage
Trial: 19443680
Drug: Telavancin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telavancin 10 mg/kg
Trial: 12623762
Drug: Troleandomycin (TAO)
RxNorm normalized name: TAO brand of troleandomycin
DrugBank: Troleandomycin (DB13179)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Troleandomycin (TAO) 500 mg daily for 2 days before omeprazole (OP) administration
Trial: 1650685
Drug: Transcatheter hepatic
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter hepatic arterial chemo-embolizations with MMC 20 mg
Trial: 1650685
Drug: Transcatheter hepatic
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter hepatic arterial chemo-embolizations with MMC 20 mg plus lipiodol 10 ml
Trial: 1650685
Drug: Transcatheter hepatic
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter hepatic arterial chemo-embolizations with MMC 20 mg plus MTXmc 150 mg
Trial: 1650685
Drug: Direct puncture
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct puncture of the main trunk of the portal vein to infuse 500 mg of 5-FU during operation
Trial: 1650685
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of MMC 20 mg through a catheter inserted into the hepatic artery 4 weeks after operation
Trial: 6131800
Drug: Naftidrofuryl (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (40 mg in 5 ml i.m. three times daily for 6 days)
Trial: 6131800
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 ml in normal saline i.m. three times daily for 6 days)
Trial: 31476429
Drug: Alprazolam (GABAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (GABAA agonist)
Trial: 31476429
Drug: Baclofen (GABAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (GABAB agonist)
Trial: 26013322
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (hypertonic saline with lidocaine)
Trial: 26013322
Drug: Open treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open treatment (hypertonic saline with lidocaine)
Trial: 26013322
Drug: Hidden treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hidden treatment (hypertonic saline with lidocaine)
Trial: 24755125
Drug: Tamsulosin hydrochloride
RxNorm normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin hydrochloride modified release capsules (0.4 mg) alone and with mirabegron (100 mg once daily)
Trial: 24755125
Drug: Co-treatment of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-treatment of mirabegron and tamsulosin
Trial: 18086052
Drug: Calcium hydroxylapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxylapatite (CaHA) gel
Trial: 2147702
Drug: Outpatient group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient group behavioral therapy including aerobic exercise (BE)
Trial: 2147702
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy only (B)
Trial: 2147702
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (BE, B, E)
Trial: 6986967
Drug: Oral mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral mercaptopurine and methotrexate for 18 months (for all children)
Trial: 31628035
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist luteal support (0.1 mg subcutaneously every other day, starting on day 3 after embryo transfer)
Trial: 31628035
Drug: HCG luteal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCG luteal support (80 µg on day 3 after embryo transfer)
Trial: 20237169
Drug: Pioglitazone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (45 mg)
Trial: 18540369
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with methylprednisolone (mPSL) and high-dose immunoglobulin (IVIg)
Trial: 18540369
Drug: Non-combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-combination therapy (IVIg alone)
Trial: 14607447
Drug: Short-term dobutamine
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term dobutamine infusion (10 microg/kg/min) in CHF patients
Trial: 14607447
Drug: 48-hour dobutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48-hour dobutamine infusion (10 microg/kg/min) in CHF patients
Trial: 14607447
Drug: Short-term dobutamine
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term dobutamine infusion (10 microg/kg/min) in matched controls
Trial: 14607447
Drug: Short-term dobutamine
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term dobutamine infusion (10 microg/kg/min) in young controls
Trial: 9161192
Drug: Oral injection
RxNorm normalized name: Iohexol 300 mg in 1 mL ORAL INJECTION, SOLUTION [OMNIPAQUE]
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral injection
Trial: 1616866
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with LHRH analogue followed by deferred orchidectomy
Trial: 3908283
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg t.i.d.) plus dipyridamole (75 mg t.i.d.)
Trial: 29357482
Drug: Acetaminophen (APAP)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (APAP) 1,000 mg/6 h for 24 h before resistance exercise
Trial: 11041320
Drug: Hydrocortisone, 20
RxNorm normalized name: Hydrocortisone, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone, 20 mg twice daily
Trial: 9048274
Drug: Ophthalmic timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic timolol (50 microL of 0.5%)
Trial: 8312212
Drug: Single insertion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single insertion of vaginal tablets of prostaglandin E2 (PGE2) containing 3mg of dinoprostin
Trial: 8312212
Drug: Single insertion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single insertion of vaginal tablets of prostaglandin E2 (PGE2)
Trial: 2655681
Drug: Frusemide 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 10 mg
Trial: 3518770
Drug: Frusemide 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 20 mg
Trial: 24529502
Drug: Clopidogrel therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel therapy (75mg/day)
Trial: 22133776
Drug: Thalidomide 400
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide 400 mg/day
Trial: 19682274
Drug: 8% lidocaine
RxNorm normalized name: LIDOCAINE 18 g in 100 g TOPICAL CREAM [Tattoo Numbing Cream 18% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% lidocaine pump spray (XPS)
Trial: 19682274
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo pump spray (PPS)
Trial: 17227903
Drug: Increased cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased cytotoxic dose intensity through conventional means (support of hematopoietic growth factors, shortening treatment intervals)
Trial: 17227903
Drug: Megadose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Megadose chemotherapy with the support of autologous bone marrow transplantation
Trial: 15096921
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Botox + Zyderm II collagen)
Trial: 12235445
Drug: Peppermint oil
RxNorm normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppermint oil (600 mg)
Trial: 12235445
Drug: Ascorbyl palmitate
RxNorm normalized name: Ascorbyl Palmitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascorbyl palmitate (500 mg)
Trial: 7989386
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (40 mg of enoxaparin the evening before the operation and once a day subsequently)
Trial: 7989386
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (5000 international units the evening before the operation and three times a day thereafter)
Trial: 2648897
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) 15‐20 micrograms/kg
Trial: 2648897
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution (meperidine 1.5 mg/kg, diazepam 0.2 mg/kg, atropine 0.02 mg/kg) 0.25 ml/kg
Trial: 31685472
Drug: CRS3123 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRS3123 200 mg
Trial: 31685472
Drug: CRS3123 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRS3123 400 mg
Trial: 31685472
Drug: CRS3123 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRS3123 600 mg
Trial: 31685472
Drug: CRS3123 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRS3123 (all doses)
Trial: 31685472
Drug: CRS3123 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRS3123 200 mg and 400 mg
Trial: 23500251
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg prasugrel loading dose
Trial: 23500251
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg ticagrelor loading dose
Trial: 19018814
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied nightly for 6 weeks with occlusion
Trial: 17298349
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate hydrofluoroalkane (FP-HFA) inhaled through the nose using a large volume spacer attached to a face mask
Trial: 17298349
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray of isotonic saline plus oral inhalation of FP-HFA through a mouthpiece attached to the same spacer
Trial: 15229463
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5FU) alone in standard de Gramont regimen (400 mg/m(2) bolus plus 600 mg/m(2) infusion)
Trial: 15229463
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5FU) plus oxaliplatin (85 mg/m(2)) in standard de Gramont regimen
Trial: 15229463
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5FU) alone in modified de Gramont regimen (400 mg/m(2) bolus plus 2400 mg/m(2) infusion)
Trial: 15229463
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5FU) plus oxaliplatin (85 mg/m(2)) in modified de Gramont regimen
Trial: 11069821
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of ENO values in steroid-naive vs steroid-treated asthmatic children
Trial: 3751735
Drug: Pentazocine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (40 mg)
Trial: 3751735
Drug: Pentazocine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (80 mg)
Trial: 3751735
Drug: Tripelennamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripelennamine (50 mg)
Trial: 3751735
Drug: Tripelennamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripelennamine (100 mg)
Trial: 3751735
Drug: Pentazocine and
RxNorm normalized name: pentazocine and naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentazocine and tripelennamine combination
Trial: 23723326
Drug: N-terminal pro-B-type
RxNorm normalized name: N-terminal pro-B-type natriuretic peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) >400 ng/l
Trial: 22950600
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (100 mg/day for 2 months)
Trial: 19465537
Drug: Moderate-dose MPH
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate-dose MPH (0.6 mg/kg)
Trial: 19465537
Drug: Low-dose MPH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose MPH (0.3 mg/kg)
Trial: 10471602
Drug: Inhaled olprinone
RxNorm normalized name: Olprinone
DrugBank: Olprinone (DB16847)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Inhaled olprinone
Trial: 6416401
Drug: Anatomical injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anatomical injection after diagnosis by selective tissue tension technique
Trial: 6416401
Drug: Tender or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tender or trigger point localisation injection